This eye-opening meta-analysis of 25 trials evaluating neoadjuvant therapies for rectal cancer (n=11,882) reports no trial-level association between rates of pathologic complete response rate and overall or even disease-free survival. Say what..? Apparently, while achieving a pCR clearly identifies which patients are likely to have better outcomes on an individual level, the fact that one therapy achieves a higher rate of pCR across a population does not translate to said therapy achieving a better survival across said population. This has big implications for therapy approvals and widespread adoption of treatment algorithms based on pCR alone. | Sugumar, JAMA Netw Open 2025

